Evaluation of the Drug –Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults

ConclusionThe inhibitory effect for CYP3A was confirmed after the last dose of ensitrelvir, and the effect diminished over time. In addition, ensitrelvir at 375/125 mg showed CYP3A inhibitory potential similar to that at 750/250 mg. These findings can be used as a clinical recommendation for prescribing ensitrelvir with regard to concomitant medications.Clinical Trial RegistrationJapan Registry of Clinical Trials identifier: jRCT2031210202.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research